The effect of the contraceptive pill on blood pressure: A randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary

Kovács, László; Bártfai, György; Apró, G; Annus, J; Bulpitt, CJ; Belsey, E M; Pinol, A.; Contraceptives, Task Force on Oral

doi:10.1016/0010-7824(86)90034-x

Cited by 13 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, vaginal rings with 15 μg of ethinyl estradiol, or oral contraception with 20 μg can still have negative cardiovascular effects . In addition, lowering the dose of estrogen does not seem to diminish the effect on blood pressure . The selection of progestin remains controversial, since progestins can have different additional effects.…”

Section: Drug Affecting Primarily the Vascular Systemmentioning

confidence: 99%

“…495,506 In addition, lowering the dose of estrogen does not seem to diminish the effect on blood pressure. 498,507 The selection of progestin remains controversial, since progestins can have different additional effects. For example, they can act as agonists or antagonists at androgen receptors, they can have estrogenic potential and the relatively new compound, drospirenone, has an antagonistic effect at mineralocorticoid receptors.…”

Section: Hormonal Contraceptionmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive review of cardiovascular toxicity of drugs and related agents

Mladěnka

Applová

Patočka

et al. 2018

Medicinal Research Reviews

203

120

View full text Add to dashboard Cite

Cardiovascular diseases are a leading cause of morbidity and mortality in most developed countries of the world. Pharmaceuticals, illicit drugs, and toxins can significantly contribute to the overall cardiovascular burden and thus deserve attention. The present article is a systematic overview of drugs that may induce distinct cardiovascular toxicity. The compounds are classified into agents that have significant effects on the heart, blood vessels, or both. The mechanism(s) of toxic action are discussed and treatment modalities are briefly mentioned in relevant cases. Due to the large number of clinically relevant compounds discussed, this article could be of interest to a broad audience including pharmacologists and toxicologists, pharmacists, physicians, and medicinal chemists. Particular emphasis is given to clinically relevant topics including the cardiovascular toxicity of illicit sympathomimetic drugs (e.g., cocaine, amphetamines, cathinones), drugs that prolong the QT interval, antidysrhythmic drugs, digoxin and other cardioactive steroids, beta‐blockers, calcium channel blockers, female hormones, nonsteroidal anti‐inflammatory, and anticancer compounds encompassing anthracyclines and novel targeted therapy interfering with the HER2 or the vascular endothelial growth factor pathway.

show abstract

Section: Drug Affecting Primarily the Vascular Systemmentioning

confidence: 99%